Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 9/20 | 0.56 |
| ▸ | CA2 | P00918 | 9/20 | 0.56 |
| ▸ | CA9 | Q16790 | 7/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | CXCR4 | P61073 | 7/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.56 |
| ▸ | CCR2 | P41597 | 1/20 | 0.56 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 6/20 | 0.53 |
| ▸ | CA7 | P43166 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9514721 | 0.84 | CA2 (0.61) | KDM4EALDH1A1LMNACA1CA2 | |
| SCHEMBL722275 | 0.83 | SIGMAR1 (0.56) | LMNASIGMAR1CXCR4MEN1CHRM2 | |
| SCHEMBL27150737 | 0.83 | HRH3 (0.64) | KDM4EALDH1A1CA1CA2CA9 | |
| Hydrochloric Acid SCHEMBL29045124 | 0.82 | CXCR4 (0.57) | LMNASIGMAR1CXCR4MEN1CHRM2 | |
| SCHEMBL11123197 | 0.80 | CA2 (0.64) | ALDH1A1LMNACA1CA2CA9 | |
| SCHEMBL18173273 | 0.80 | CA1 (0.61) | ALDH1A1CA1CA2CA9CA12 | |
| Hydrochloric Acid SCHEMBL5573232 | 0.80 | CXCR4 (0.78) | LMNASIGMAR1CXCR4MEN1CHRM2 | |
| SCHEMBL1259387 | 0.80 | CXCR4 (0.81) | ALDH1A1SIGMAR1CXCR4MEN1CHRM2 | |
| SCHEMBL25145674 | 0.80 | SIGMAR1 (0.51) | LMNASIGMAR1CXCR4MEN1CHRM2 | |
| SCHEMBL2551595 | 0.80 | TSHR (0.58) | ALDH1A1SIGMAR1CXCR4MEN1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106946812-B | Design, synthesis and evaluation of procaspase activating compounds as personalized anticancer agents | 伊利诺伊大学评议会 | 2020-10-09 | — | — | CN | disclosed |
| CN-106946812-A | It is used as the design, synthesis and evaluation of the former activating compounds of the Caspase of customized anti-cancer medicine | 伊利诺伊大学评议会 | 2017-07-14 | — | — | CN | disclosed |
| US-9643960-B2 | Procaspase activating compounds | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-05-09 | — | — | US | disclosed |
| US-9643960-B2 | Procaspase activating compounds | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-05-09 | — | — | US | disclosed |
| US-9643960-B2 | Procaspase activating compounds | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-05-09 | — | — | US | disclosed |
| EP-2393794-B1 | DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS | UNIV ILLINOIS (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-2393794-B1 | DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS | UNIV ILLINOIS (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20150344452-A1 | PROCASPASE ACTIVATING COMPOUNDS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344452-A1 | PROCASPASE ACTIVATING COMPOUNDS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344452-A1 | PROCASPASE ACTIVATING COMPOUNDS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-12-03 | — | — | US | disclosed |
| US-8778945-B2 | Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778945-B2 | Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778945-B2 | Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-07-15 | — | — | US | disclosed |
| CN-102438998-A | Design, synthesis and evaluation of procaspase activating compounds as personalized anticancer agents | UNIV ILLINOIS | 2012-05-02 | — | — | CN | disclosed |
| US-20120040995-A1 | DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040995-A1 | DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040995-A1 | DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-02-16 | — | — | US | disclosed |
| EP-2393794-A1 | DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS | The Board Of Trustees Of The UniversityOf Illinois (US) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010091382-A1 | DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010091382-A1 | DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344452-A1 | PROCASPASE ACTIVATING COMPOUNDS | CASP3, CASP6, BAX | KDM4E 2112/4885ALDH1A1 892/4885LMNA 307/4885 |
| US-20120040995-A1 | DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS | CASP3, CASP6, CASP14 | KDM4E 1672/4885ALDH1A1 1256/4885LMNA 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.